TY - JOUR
T1 - Optimizing the Cas13 antiviral train
T2 - cargo and delivery
AU - Sharma, Shruti
AU - Myhrvold, Cameron
N1 - Publisher Copyright:
© 2023 The Authors. Published under the terms of the CC BY 4.0 license.
PY - 2023/7/10
Y1 - 2023/7/10
N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 2020 highlighted the need for rapid, widespread responses against infectious disease. One such innovation uses CRISPR-Cas13 technology to directly target and cleave viral RNA, thereby inhibiting replication. Due to their programmability, Cas13-based antiviral therapies can be rapidly deployed to target emerging viruses, in comparison with traditional therapeutic development that takes at least 12–18 months, and often many years. Moreover, similar to the programmability of mRNA vaccines, Cas13 antivirals can be developed to target mutations as the virus evolves.
AB - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 2020 highlighted the need for rapid, widespread responses against infectious disease. One such innovation uses CRISPR-Cas13 technology to directly target and cleave viral RNA, thereby inhibiting replication. Due to their programmability, Cas13-based antiviral therapies can be rapidly deployed to target emerging viruses, in comparison with traditional therapeutic development that takes at least 12–18 months, and often many years. Moreover, similar to the programmability of mRNA vaccines, Cas13 antivirals can be developed to target mutations as the virus evolves.
UR - http://www.scopus.com/inward/record.url?scp=85160220101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160220101&partnerID=8YFLogxK
U2 - 10.15252/emmm.202217146
DO - 10.15252/emmm.202217146
M3 - Comment/debate
C2 - 37231981
AN - SCOPUS:85160220101
SN - 1757-4676
VL - 15
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 7
M1 - e17146
ER -